Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 947-953

  Velez Montoya, Raul ^a   Clapp, Carmen ^b   Rivera, Jose Carlos ^b   Garcia Aguirre, Gerardo ^a   Morales Cantón, Virgilio ^a   Fromow Guerra, Jans ^a   Guerrero Naranjo, Jose Luis ^a   Quiroz Mercado, Hugo ^c  

^a Asociacion para Evitar la Ceguera en Mexico IAP   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Late stages; ROP; VEGF

Indexed keywords

VASCULOTROPIN;

AQUEOUS HUMOR; ARTICLE; B SCAN; CLINICAL ARTICLE; CONGENITAL CATARACT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; INTERVENTION STUDY; MALE; PHACOEMULSIFICATION; PROTEIN BLOOD LEVEL; RETROLENTAL FIBROPLASIA; STAGING; SUBRETINAL FLUID; VITRECTOMY; VITREOUS BODY;

EID: 77956130702     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s11650     Document Type: Article

References (39)

1. Lermann VL, Fortes Filho JB, Procianoy RS. The prevalence of retinopathy of prematurity in very low birth weight newborn infants. J Pediatr. 2006;82:27-32.
2. Karna P, Muttineni J, Angell L, Karmaus W. Retinopathy of prematurity and risk factors: a prospective cohort study. BMC Pediatr. 2005;5:18.
3. Chawla D, Agarwal R, Deorari AK, Paul VK. Retinopathy of prematurity. Indian J Pediatr. 2008;75:73-76.
4. Madanlou HD, Gharraee Z, Hasan J, et al. Ontogeny of VEGF, IGF.I and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci. 2006;47:738-744.
5. Sonmez K, Drenser KA, Capone A Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008;115:1065-1070.e1.
6. Kinsey VE, Arnold HJ, Kalina RE, et al. PaO2 levels and retrolental fibroplasia: a report of the cooperative study. Pediatrics. 1977;60: 655-668.
7. Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326:1050-1054.
8. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:1599-1603.
9. Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165-2169.
10. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol. 2000;156:1337-1344.
11. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996;114:1219-1228.
12. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGFsurvival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804-5808.
13. Yoo MH, Hyun HJ, Koh JY, Yoon YH. Riluzole inhibits VEGFinduced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. Invest Ophthalmol Vis Sci. 2005; 46:4780-4787.
14. Flynn JT, Chan-Ling T. Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol. 2006;142:46-59.
15. Kieselbach GF, Ramharter A, Baldissera I, Kralinger MT. Laser photocoagulation for retinopathy of prematurity: structural and functional outcome. Acta Ophthalmol Scand. 2006;84:21-26.
16. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis. 2004;10:512-520.
17. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2003;44:781-790.
18. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002;134:348-353.
19. Villegas-Becerril E, González-Fernández R, Perula-Torres L, Gallardo-Galera JM. IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol. 2006;81:641-646.
20. Cooke RW, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2004;45:1712-1715.
21. Itakura H, Kishi S, Kotajima N, Murakami M. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. Ophthalmology. 2004;111:1880-1884.
22. Ozkan H, Duman N, Kumral A, et al. Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity. Physiol Res. 2006;55:267-275.
23. Chowers I, Banin E, Hemo Y, et al. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Br J Ophthalmol. 2001;85:991-995.
24. Committee for the classification of retinopathy of prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130-1134.
25. Committee for the classification of retinopathy of prematurity. An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. Arch Ophthalmol. 1987;105:906-912.
26. Hutcheson KA. Retinopathy of prematurity. Curr Opin Ophthalmol. 2003;14:286-290.
27. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med. 1995;1:182-193.
28. Gariano RF, Kalina RE, Hendrickson AE. Normal and pathological mechanisms in retinal vascular development. Surv Ophthalmol. 1996;40:481-490.
29. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006;84:282-288.
30. Aranda J, Rivera JC, Jeziorski MC, et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci. 2005;46:2947-2953.
31. Lee H, Struman I, Clapp C, Martial J, Weiner RI. Inhibition of urokinase activity by the antiangiogenic factor 16 K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology. 1998;139:3696-3703.
32. Dueñas Z, Rivera JC, Quiroz-Mercado H, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci. 2004;45:2049-2055.
33. Clapp C, Aranda J, González C, Jeziorski MC, Martínez de la Escalera G. Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab. 2006;17:301-307.
34. Modanlou HD, Gharraee Z, Hasan J, Waltzman J, Nageotte S, Beharry KD. Ontogeny of VEGF, IGF-I, and GH in neonatal rat serum, vitreous fluid, and retina from birth to weaning. Invest Ophthalmol Vis Sci. 2006;47:738-744.
35. Moromizato Y, Hayashi H, Kato H, et al. Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment [Japanese]. Nippon Ganka Gakkai Zasshi. 1997;101:498-502.
36. Vinores SA, Chan CC, Vinores MA, et al. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998;89:43-50.
37. Hu DN, Ritch R, Liebmann J, et al. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410.
38. Borazan M, Karalezli A, Kucukerdonmez C, et al. Aqueous humor and plasma levels of vascular endothelial growth factor and nitric oxide in patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. J Glaucoma. 2010;19:207-211.
39. Hartnett ME, Gilbert MM, Hirose T, et al. Glaucoma as a cause of poor vision in severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 1993;231:433-438.